- Trials with a EudraCT protocol (113)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
113 result(s) found for: Fertilization.
Displaying page 5 of 6.
EudraCT Number: 2013-002482-19 | Sponsor Protocol Number: 13EU/FSH01 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:IBSA Institut Biochimique S.A. | |||||||||||||
Full Title: Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles. | |||||||||||||
Medical condition: female infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001942-28 | Sponsor Protocol Number: APD334-003 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerativ... | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) ES (Completed) DE (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) PL (Completed) BG (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004772-36 | Sponsor Protocol Number: 38821 | Start Date*: 2006-06-30 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38819 for Org 36286 (corifollitropin alfa) | |||||||||||||
Medical condition: Controlled Ovarian Stimulation (COS) to induce the development of multiple follicles in patients participating in an Assisted Reproductive Technology (ART) program | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) ES (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002812-33 | Sponsor Protocol Number: 204824 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function ... | |||||||||||||
Medical condition: Delayed Graft Function in Adult Subjects After Renal Transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001726-22 | Sponsor Protocol Number: COLIGROW | Start Date*: 2022-12-12 | |||||||||||
Sponsor Name:Dr. Ignacio Herraiz García | |||||||||||||
Full Title: COok's ballon versus dinoprostone for Labor Induction of term pregnancies with fetal GROWth restriction (COLIGROW study). | |||||||||||||
Medical condition: Induction of term pregnancies with fetal growth restriction. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005185-18 | Sponsor Protocol Number: HEPA-CRV431-207 | Start Date*: 2022-07-13 | |||||||||||
Sponsor Name:Hepion Pharmaceuticals, Inc. | |||||||||||||
Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN... | |||||||||||||
Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004214-35 | Sponsor Protocol Number: P170706J | Start Date*: 2021-03-18 | |||||||||||
Sponsor Name:Assistance Publique Hôpitaux de Paris | |||||||||||||
Full Title: Amélioration des taux de Naissance après ICSI, par le cpFT. Etude multicentrique prospective randomisée. « FERTICSI ». | |||||||||||||
Medical condition: infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004329-21 | Sponsor Protocol Number: PE-PMA | Start Date*: 2021-02-01 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Reduction of progesterone elevation at trigger in poor responder Bologna’ criteria patients after controlled ovarian stimulation with long acting standard stimulation protocol compared with convent... | |||||||||||||
Medical condition: Patient with poor ovarian response | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001677-31 | Sponsor Protocol Number: AMB-001 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop... | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003879-42 | Sponsor Protocol Number: 2021/ABM/03/00006 | Start Date*: 2023-04-12 | ||||||||||||||||
Sponsor Name:Medical Univeristy of Bialystok | ||||||||||||||||||
Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility | ||||||||||||||||||
Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002383-32 | Sponsor Protocol Number: 997 | Start Date*: 2021-07-02 | ||||||||||||||||
Sponsor Name:Biotest AG | ||||||||||||||||||
Full Title: Prevention of maternal-fetal Cytomegalovirus transmission after primary maternal infection with gestational age ≤ 14 weeks – an open-label, single-arm, prospective trial investigating efficacy and ... | ||||||||||||||||||
Medical condition: Prevention of maternal-fetal cytomegalovirus transmission after primary maternal infection with gestational age ≤ 14 weeks | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001669-17 | Sponsor Protocol Number: 000004 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stim... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003590-24 | Sponsor Protocol Number: LPL104884 | Start Date*: 2006-03-01 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje... | ||
Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002109-12 | Sponsor Protocol Number: APD334-005 | Start Date*: 2016-01-08 | |||||||||||
Sponsor Name:Arena Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) ES (Completed) GB (Completed) HU (Completed) CZ (Completed) LT (Completed) BE (Completed) BG (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001232-11 | Sponsor Protocol Number: 200622 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophi... | |||||||||||||
Medical condition: severe hypereosinophilic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000089-45 | Sponsor Protocol Number: OT-15-001 | Start Date*: 2016-11-07 | |||||||||||
Sponsor Name:Orbus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur Af... | |||||||||||||
Medical condition: Anaplastic Astrocytoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) FR (Completed) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003797-40 | Sponsor Protocol Number: APD334-006 | Start Date*: 2017-02-23 |
Sponsor Name:Arena Pharmaceuticals, Inc. | ||
Full Title: A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations | ||
Medical condition: Active Skin Extra-Intestinal Manifestations in Inflammatory Bowel Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003309-88 | Sponsor Protocol Number: ROR-PH-302 | Start Date*: 2020-06-02 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He... | |||||||||||||
Medical condition: pulmonary arterial hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001033-39 | Sponsor Protocol Number: VIR-2218-1006 | Start Date*: 2022-08-30 | |||||||||||
Sponsor Name:Vir Biotechnology, Inc. | |||||||||||||
Full Title: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic HBV infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002671-10 | Sponsor Protocol Number: 203820 | Start Date*: 2016-12-20 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A two-part trial to evaluate the safety, tolerability, clinical effect and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis | |||||||||||||
Medical condition: Plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
